Holen Sie sich die Stockscreener-App
3.14
0.32%
0.01
Schlusskurs vom Vortag:
$3.13
Offen:
$3.12
24-Stunden-Volumen:
2.38M
Relative Volume:
0.52
Marktkapitalisierung:
$832.56M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-11.21
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
-1.57%
1M Leistung:
-10.54%
6M Leistung:
+71.58%
1J Leistung:
+106.58%
1-Tages-Spanne:
$3.03
$3.15
1-Wochen-Bereich:
$2.98
$3.21
52-Wochen-Spanne:
$1.24
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie AKBA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
3.14 | 829.90M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
156.40 | 68.60B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.99 | 47.28B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.80 | 43.41B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.38 | 20.69B | 16.70B | -157.13M | 1.19B | -0.155 |
|
NBIX
Neurocrine Biosciences Inc
|
139.60 | 13.78B | 2.41B | 305.80M | 492.20M | 2.95 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Measuring Akebia Therapeutics Inc.’s beta against major indicesCEO Change & Free AI Powered Buy and Sell Recommendations - Newser
Will Akebia Therapeutics Inc. outperform the marketJuly 2025 Weekly Recap & Weekly High Potential Alerts - Newser
Strategies to average down on Akebia Therapeutics Inc.Quarterly Portfolio Review & Precise Trade Entry Recommendations - Newser
Analyzing drawdowns of Akebia Therapeutics Inc. with statistical toolsQuarterly Profit Summary & Daily Volume Surge Signals - Newser
What Fibonacci levels say about Akebia Therapeutics Inc. reboundPortfolio Return Report & Technical Entry and Exit Tips - Newser
Sentiment analysis tools applied to Akebia Therapeutics Inc.Bond Market & Verified High Yield Trade Plans - Newser
Using Bollinger Bands to evaluate Akebia Therapeutics Inc.2025 Market Trends & Fast Entry Momentum Trade Alerts - Newser
Visual trend scoring systems applied to Akebia Therapeutics Inc.Quarterly Earnings Summary & Capital Efficient Trading Techniques - Newser
Biotech Movers: Akebia Shares Down After Pricing Stock Offering - TheStreet
What’s the recovery path for long term holders of Akebia Therapeutics Inc.Volume Spike & Safe Capital Growth Tips - Newser
Is Akebia Therapeutics Inc. forming a bottoming base2025 Top Gainers & Capital Efficient Trade Techniques - Newser
Price momentum metrics for Akebia Therapeutics Inc. explainedPortfolio Gains Summary & Expert Curated Trade Setups - Newser
Understanding Akebia Therapeutics Inc.’s price movementWeekly Trade Recap & AI Based Buy/Sell Signal Reports - Newser
What is Akebia Therapeutics Inc. s 5 year growth outlookPortfolio Performance Report & Intraday High Probability Alerts - sundaytimes.kr
Chart based exit strategy for Akebia Therapeutics Inc.Portfolio Gains Summary & Low Risk High Win Rate Picks - Newser
How to interpret RSI for Akebia Therapeutics Inc. stockWeekly Profit Analysis & Smart Allocation Stock Reports - Newser
News impact scoring models applied to Akebia Therapeutics Inc.Portfolio Value Report & Reliable Price Breakout Alerts - Newser
Detecting support and resistance levels for Akebia Therapeutics Inc.2025 Technical Patterns & Free Expert Approved Momentum Trade Ideas - Newser
Published on: 2025-08-29 01:11:05 - Newser
Akebia Therapeutics Inc. stock trend forecast2025 Dividend Review & Verified Entry Point Signals - Newser
Why Akebia Therapeutics Inc. stock attracts strong analyst attentionRecession Risk & AI Forecast Swing Trade Picks - Newser
Published on: 2025-08-28 12:35:30 - Newser
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):